Verzenio (Abemaciclib) .
Verzenio (Abemaciclib) is a drug for the treatment of advanced or metastatic breast cancers. It acts as a CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthrough therapy for breast cancer by the U.S. Food and Drug Administration.
Verzenio is a prescription medicine used to treat a type of breast cancer. It is a medicine you can take if:
- You have a type of breast cancer called HR+/HER2− (hormone receptor positive/human epidermal growth factor receptor 2 negative) and the cancer has spread to other parts of the body (metastasized)
- Verzenio is given in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, in combination with fulvestrant in women whose disease has progressed after hormonal therapy, or alone in women whose disease has progressed after hormone therapy and prior chemotherapy
It is not known if Verzenio is safe and effective in children.
50 mg, 100 mg, 150 mg, 200 mg